The Effect of Plasma Osmolality on Brain Glutamate
Information source: Yale University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: furosemide, Na supplements (Drug)
Phase: Phase 1/Phase 2
Status: Completed
Sponsored by: Yale University Official(s) and/or principal investigator(s): Handan Gunduz-Bruce, M.D., Principal Investigator, Affiliation: Yale School of Medicine
Summary
This study is designed to test the hypothesis that plasma osmolality is linked with cortical
glutamate concentrations in the brain. It also investigates whether the glutamate response
in schizophrenia is enhanced compared to healthy controls.
Clinical Details
Official title: The Role of Cortical Glutamate and GABA in Brains Osmotic Regulation: A Pilot Study in Healthy Volunteers and in Patients With Schizophrenia
Study design: Intervention Model: Parallel Assignment, Masking: Open Label
Primary outcome: Cortical glutamate concentration
Secondary outcome: Cognitive function
Eligibility
Minimum age: 21 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion criteria for healthy controls
1. Ages of 21-45 years from all ethnic backgrounds.
2. Male or female.
3. Written informed consent.
4. Female subjects will be studied during the follicular phase of their menstrual
cycle.*
Exclusion criteria for healthy controls
1. DSM-IV diagnosis of psychotic, anxiety, mood disorder.
2. A history of significant medical/neurological disease. Unstable medical condition
based on EKG, vital signs, physical examination and laboratory work-up (CBC with
differential, SMA-7, LFTs, TFTs, UA, Utox, Urine pregnancy test, folic acid, B12
levels).
3. History of allergies to drugs such as sulfa, multiple adverse drug reactions or known
allergy to furosemide.
4. Any medication that in the opinion of the PI could interfere with either the safety
of the study and/or the outcome measures, such as over the counter cough suppressants
or antihistamines.
5. History of major psychiatric disorder in first-degree relatives.
6. Current substance abuse/dependency determined by plasma and urine toxicology.
7. Current treatment with medications with psychotropic effects.
8. Current pregnancy, unsatisfactory birth control method report for females.
9. Education < 12th grade.
10. Non-English speaking.
Inclusion criteria for patients with schizophrenia
1. Ages of 21-45 years from all ethnic backgrounds.
2. Male or female.
3. Written informed consent.
4. DSM-IV diagnosis of schizophrenia or schizoaffective disorder.
5. For treated patients: The patient has been on a stable dose of medications
(antipsychotics, antidepressants) for the past month and does not require a change of
medications or dose adjustment at study entry.
6. For untreated patients: Has refused to be treated with medications, maintains regular
clinic appointments with the clinicians, and does not pose an imminent danger to
himself or others.
7. Female subjects will be studied during the follicular phase of their menstrual
cycle*.
Exclusion criteria for patients with schizophrenia
1. A history of significant medical/neurological disease. Unstable medical condition
based on EKG, vital signs, physical examination and laboratory work-up (CBC with
differential, SMA-7, LFTs, TFTs, UA, Utox, Urine pregnancy test, folic acid, B12
levels).
2. Orthostatic systolic blood pressure change>20 mmHg or orthostatic pulse change>20
bpm.
3. History of polydipsia/hyponatremia**.
4. History of allergies to drugs such as sulfa, multiple adverse drug reactions or known
allergy to furosemide.
5. Any medication that in the opinion of the PI could interfere with either the safety
of the study and/or the outcome measures, such as over the counter cough suppressants
or antihistamines.
6. Current use of lithium (lithium directly interferes with electrolyte balance).
7. Currently on clozapine as clozapine may interfere with brain water regulation
(Leadbetter and Shutty, 1994).
8. Current substance abuse/dependency determined by plasma and urine toxicology.
9. Current treatment with benzodiazepines or mood stabilizers (these medications can
alter glutamate transmission).
10. Current pregnancy, unsatisfactory birth control method report for females.
11. IQ < 70 as determined by Wechsler Abbreviated Scale of Intelligence.
12. Non-English speaking
Locations and Contacts
34 Park Street, CMHC, New Haven, Connecticut 06519, United States
Additional Information
Starting date: March 2007
Last updated: August 23, 2012
|